Fitting our data, ADAM10 and ADAM17 (over) expression levels likewise significantly correlates with tumor grade in glioma, and both ADAMs are discussed as prognostic markers and therapeutic targets [51,52,53]. This evidence concerns the gene ADAM10 and central nervous system cancer.